Genscript Biotech Corporation (G51) — Cash Flow-to-Debt Ratio
Genscript Biotech Corporation (G51) has a Cash Flow-to-Debt Ratio of -0.07x as of June 2023, meaning its operating cash flow of €-93.58 Million could theoretically repay 0% of its total liabilities (€1.30 Billion) in one year. See cash generation quality of Genscript Biotech Corporation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Genscript Biotech Corporation Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Genscript Biotech Corporation across 10 annual periods. Also explore Genscript Biotech Corporation net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Genscript Biotech Corporation (2016–2025)
Year-by-year debt coverage analysis for Genscript Biotech Corporation. For market capitalisation and broader financial context, see Genscript Biotech Corporation (G51) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.37x | €325.52 Million | €888.59 Million | ▲ +362.4% |
| 2024 | 0.08x | €75.65 Million | €954.91 Million | ▲ +137.1% |
| 2023 | -0.21x | €-286.91 Million | €1.34 Billion | ▼ -110.2% |
| 2022 | -0.10x | €-120.29 Million | €1.18 Billion | ▲ +15.3% |
| 2021 | -0.12x | €-136.79 Million | €1.14 Billion | ▲ +49.8% |
| 2020 | -0.24x | €-151.09 Million | €631.82 Million | ▼ -312.8% |
| 2019 | -0.06x | €-29.95 Million | €517.11 Million | ▼ -108.0% |
| 2018 | 0.73x | €307.66 Million | €423.68 Million | ▲ +837.8% |
| 2017 | 0.08x | €21.37 Million | €275.94 Million | ▼ -90.2% |
| 2016 | 0.79x | €33.27 Million | €42.01 Million | — |